Unless they have plans to increase the specificity of these activated neutrophils, this appears to have limited long term usefulness. Upregulating inflammatory

Unless they have plans to increase the specificity of these activated neutrophils, this appears to have limited long term usefulness. Upregulating inflammatory cytokine expression in a nonspecific manner like this has undesirable consequences. It is like having a rat infestation in your home and your new solution is to add some dynamite in with your rat traps. Anyone who has managed cancer patients knows that downstream effects of excessive/uncontrolled inflammation contribute substantially to patient morbidity. Dysregulated edothelial permeability, pleural and peritoneal effusion, coagulopathies, glomerular injury, hypoproteinemia, hypotension, tumor lysis syndrome... I could go on and on, but my point is there is a web of interconnected problems you bring on board when you drive inflammation. The name of the game is isolated targeting of neoplastic cells in a controlled manner that minimizes inflammation. That is very difficult to do, but our best tools seem to be developing in the fine-grained depths of immunology. Not strapping kamikaze backpacks to neutrophils.